Boundless Bio, Current Debt
| BOLD Stock | USD 2.59 0.07 2.78% |
Boundless Bio, Common holds a debt-to-equity ratio of 0.078. At present, Boundless Bio,'s Short Term Debt is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 0.74, whereas Interest Debt Per Share is forecasted to decline to 0.10. . Boundless Bio,'s financial risk is the risk to Boundless Bio, stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Boundless Bio,'s liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Boundless Bio,'s cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Boundless Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Boundless Bio,'s stakeholders.
For most companies, including Boundless Bio,, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Boundless Bio, Common, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Boundless Bio,'s management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.4457 | Book Value 8.055 | Return On Assets (0.24) | Return On Equity (0.36) |
Boundless |
Boundless Bio, Financial Rating
Boundless Bio, Common financial ratings play a critical role in determining how much Boundless Bio, have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Boundless Bio,'s borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (5.40) | Unlikely Manipulator | View |
Boundless Bio, Common Debt to Cash Allocation
Many companies such as Boundless Bio,, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Boundless Bio, Common currently holds 2.19 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Boundless Bio, Common has a current ratio of 12.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Boundless Bio,'s use of debt, we should always consider it together with its cash and equity.Boundless Bio, Total Assets Over Time
Boundless Bio, Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Boundless Bio, uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Boundless Bio, Debt Ratio | 2.73 |
Boundless Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Boundless Bio, Use of Financial Leverage
Boundless Bio,'s financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Boundless Bio,'s total debt position, including all outstanding debt obligations, and compares it with Boundless Bio,'s equity. Financial leverage can amplify the potential profits to Boundless Bio,'s owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Boundless Bio, is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 2.2 M | 3.3 M | |
| Net Debt | -21.5 M | -22.6 M | |
| Short Term Debt | 2.2 M | 2.2 M | |
| Net Debt To EBITDA | 0.44 | 0.74 | |
| Debt To Equity | 0.02 | 0.03 | |
| Interest Debt Per Share | 0.14 | 0.10 | |
| Debt To Assets | 0.02 | 0.03 | |
| Long Term Debt To Capitalization | 0.01 | 0.02 | |
| Total Debt To Capitalization | 0.02 | 0.03 | |
| Debt Equity Ratio | 0.02 | 0.03 | |
| Debt Ratio | 0.02 | 0.03 | |
| Cash Flow To Debt Ratio | (13.76) | (14.44) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out the analysis of Boundless Bio, Fundamentals Over Time. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.